Sun Pharma Partners Report Clinical Updates on Fibromun and Nidlegy
Sun Pharmaceutical Industries Limited announced updates on Fibromun and Nidlegy, based on clinical data reported by its partner, Philogen, as part of Philogen’s financial results.Regarding Fibromun, the Phase II FLASH study in last-line soft tissue sarcoma did not meet its primary endpoint for Progression Free Survival (PFS), enrolling 94 patients randomized 1:1 to receive either Fibromun + dacarbazine or dacarbazine alone. Similarly, the Phase II GLIOSTAR clinical trial in 163 second-line glioblastoma patients also did not meet its primary endpoint. However, survival improvements were observed in GLIOSTAR among patients with limited exposure to alkylating agents...